Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
Sponsor: Karolinska Institutet
Summary
People with newly diagnosed type 2 diabetes treated with metformin that have not reached their HbA1c target (42-64 mmol/mol) will be recruited to the study. If they fulfill the inclusion and none of the exclusion criteria, they will be, after signing informed consent, randomized to a six-month intervention with either pioglitazone, empagliflozin or semaglutide. Fat biopsies are obtained from the subcutaneous abdominal area before and after a hyperinsulinemic-euglycemic clamp at baseline and after six months. Participants are regularly followed during this the intervention. The overall goal is to determine how antidiabetic-drugs affect white adipose tissue cellularity and whether adipose heterogeneity impacts on drug response. The primary outcome measure is the change in fat tissue lipolysis (glycerol release in isolated fat cells after hormone stimulation) before and after treatment.
Official title: Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide
Key Details
Gender
All
Age Range
30 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-02-08
Completion Date
2032-12-31
Last Updated
2025-02-26
Healthy Volunteers
No
Conditions
Interventions
Pioglitazone 45 mg
Starts with 45 mg
Empagliflozin 25 MG
Starts with 25 mg
Semaglutide 7 MG
Starts with 3 mg daily for the first 2 weeks
Locations (1)
Karolinska University Hospital
Stockholm, Sweden